Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related